SCHEMBL8230499

SCHEMBL8230499

C/C(=N\Nc1ccc(I)cc1)c1ccncc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.71
KDM4E B2RXH2 2/20 0.71
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
GAA P10253 7/20 0.58
MAPT P10636 6/20 0.58
GFER P55789 4/20 0.58
TDP1 Q9NUW8 2/20 0.58
POLB P06746 1/20 0.58
RECQL P46063 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
MTOR P42345 2/20 0.49
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
HTT P42858 2/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21812480 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL21812481 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL8228501 0.83 GAA (0.55) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL10067333 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL2061789 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL1001084 0.83 GAA (0.55) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL8225127 0.81 RAB9A (0.62) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL15217655 0.77 MAPT (0.72) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL5780133 0.74 ALDH1A1 (0.58) ALDH1A1KDM4EMEN1KMT2AGAA
SCHEMBL10105308 0.73 KMT2A (0.72) ALDH1A1KDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
EP-2029546-B1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER SCHERING PHARMA AG (DE) 2010-07-28 EP disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
WO-2007137791-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF AHR, CYP2C19, PAH ALDH1A1 318/4885KDM4E 1481/4885MEN1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.